Stock events for Plus Therapeutics, Inc. (PSTV)
Several events have impacted Plus Therapeutics, Inc. (PSTV) stock price over the past six months. Plus Therapeutics announced a new Category III CPT Code for Convection-Enhanced Delivery used with REYOBIQ™. The company provided a business update on its REYOBIQ™ clinical program and U.S. CNSide® commercialization, outlining key 2026 milestones. Plus Therapeutics announced the pricing of an upsized $15 million public offering of 39,473,684 units at $0.38 per unit, which included common stock and warrants. The company completed a Type B meeting with the FDA to discuss a potential pivotal trial strategy for REYOBIQ™ in leptomeningeal metastases. Plus Therapeutics' subsidiary, CNSide Diagnostics, LLC, was granted lab licenses for CNSide testing in the state of California. Plus Therapeutics announced the expansion of its CNSide team and the issuance of inducement grants. Plus Therapeutics highlighted three REYOBIQ™ clinical data presentations at the 2025 WFNOS/SNO Annual Meeting. Plus Therapeutics reported a quarterly loss of $0.01 per share, beating the Zacks Consensus Estimate, but missed revenue estimates for the quarter ended June 2025. As of March 5, 2026, the share price was $0.30 per share, a 79.51% decline over the past year.
Demand Seasonality affecting Plus Therapeutics, Inc.’s stock price
There is no apparent demand seasonality for Plus Therapeutics, Inc.'s products and services. Demand is driven by medical need and clinical progress rather than seasonal fluctuations.
Overview of Plus Therapeutics, Inc.’s business
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics and diagnostic services for cancers, especially those affecting the brain and central nervous system. Their core business involves developing radioactive drug formulations to deliver high-dose, localized radiation to CNS tumors. The lead radiotherapeutic candidate is REYOBIQ™, under clinical evaluation for various CNS cancers. They also develop Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM) for solid organ cancers. Plus Therapeutics commercializes a molecular diagnostic service called CNSide® through its subsidiary CNSide Diagnostics, LLC.
PSTV’s Geographic footprint
Plus Therapeutics, Inc. is headquartered in Houston, Texas, with additional laboratories and clean rooms also in Houston. The company aims to expand its operations and market reach beyond the United States. Its CNSide diagnostic platform has expanded its commercial presence by securing a national policy agreement with UnitedHealthcare, providing coverage for over 51 million people across the U.S.
PSTV Corporate Image Assessment
Plus Therapeutics has maintained a generally positive reputation among analysts, with a consensus rating of "Moderate Buy". The average price target from analysts is $5.80. Positive clinical data presentations for REYOBIQ™ at major oncology meetings, a successful Type B meeting with the FDA regarding REYOBIQ™ for leptomeningeal metastases, expansion of the CNSide diagnostic platform, and approval of a new Category III CPT Code for Convection-Enhanced Delivery used with REYOBIQ™ have positively impacted the company's reputation. The stock price decline appears related to broader market conditions and financing activities.
Ownership
Plus Therapeutics, Inc. has 32 institutional owners and shareholders holding a total of 11,565,373 shares. Approximately 3.16% of the company's stock is owned by institutional investors, 0.38% by insiders, and 96.46% by public companies and individual investors (retail investors). Major institutional owners include Vanguard Group Inc, L1 Global Manager Pty Ltd, and BlackRock, Inc. Vanguard owns the most shares of Plus Therapeutics.
